[Diagnosis and treatment of inflammatory diseases of the mammary ducts]. / Osobennosti diagnostiki i lecheniya vospalitel'nykh zabolevanii molochnykh protokov.

AIM: The analysis and popularization of the own experience of ultrasonic diagnostics and minimal invasive interventions for inflammatory diseases of the mammary ducts. PATIENTS AND METHODS: 249 women were observed: 182 (73.1%) cases of periductal mastitis and 67 (26.9%) cases of purulent galactophoritis. Patients with purulent galactophoritis were divided into 2 groups (main and control). The main group consisted of 50 patients after minimal invasive interventions, control - 17 women after traditional surgery. RESULTS: The main US signs of periductal mastitis and purulent galactophoritis were detected. Purulent galactophoritis is associated with the diameter of mammary duct less than 4 mm, ductal content flotation and stream-effect (coloring of dilated duct in Doppler mode). It was proposed the method of US-assisted mini-invasive retrograde drainage of mammary ducts with aspiration of purulent content through the natural orifice in the nipple. This method doesn't demand hospital stay, reduces duration of treatment by 14 days and doesn't cause the cosmetic defects in comparison with traditional surgical approach. CONCLUSION: Inflammatory diseases of the mammary ducts are represented by the different nosological forms - periductal mastitis (73.1%) and purulent galactophoritis (26.9%). In view of typical ultrasonic picture in patients with purulent galactophoritis US-assisted mini-invasive retrograde drainage of mammary ducts with aspiration of purulent content through the natural orifice in the nipple is advisable. This method has significant advantages in comparison with traditional surgery and may be recommended for widespread clinical use.

[Effect of synthetic proteasomal inhibitor MG132 on dynamics of EGF-receptor complexes endocytosis in A431 cells]. / Vliianie sinteticheskogo ingibitora proteasom MG132 na dinamiku éndotsitoza EFR-retseptornykh kompleksov v kletkakh A431.

The effect of proteasomal activity suppression induced by MG132, a synthetic proteasomal inhibitor of EGF-receptor complexes endocytosis in human epidermoid carcinoma A431 cell line, was studied. Using subcellular fractionation in 17% Percoll gradient, it was demonstrated that the addition of MG132 to the cells 15 min following stimulation of EGF endocytosis resulted in a slight accumulation of 125I-EGF in early endosomes, and in much more significant accumulation of the labeled growth factor in late endosomes/lysosomes, as compared to untreated cells. The release of 125I-EGF degradation products into the incubation medium was significantly (3-12-fold) inhibited in the presence of MG132. At the same time biochemical analysis has demonstrated that the EGF receptor itself is not a direct target of proteasomes, since it is revealed as a full-length protein with native mol. mass (170 kDa) in fractions of early and late endosomes and lysosomes. Possible mechanisms of the MG132 effect on intracellular processing of EGF-receptor complexes are discussed.